Affiliations: [a]
National Hospital of Sri Lanka, Colombo, Sri Lanka
| [b] Neurosciences Group, Nuffield Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
| [c] Human Genetics Unit, University of Colombo, Colombo, Sri Lanka
| [d] Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
Correspondence:
[*]
Correspondence to: Inuka Kishara Gooneratne, 10/1 Borella Cross Road, Colombo 8, Sri Lanka. Tel.: +94 112773662903; E-mail: kishig@gmail.com.
Abstract: Congenital myasthenic syndromes (CMS) result from genetic mutations that cause aberrations in structure and/or function of proteins involved in neuromuscular transmission. The slow-channel CMS (SCCMS) is an autosomal dominant postsynaptic defect caused by mutations in genes encoding alpha, beta, delta, or epsilon subunits of the acetylcholine receptor resulting in a functional defect which is an increase of the opening time of the receptor. We report a case of SCCMS due to a heterozygous mutation in the M2 domain of the AChR alpha subunit - CHRNA1:ENST00000348749.6:exon7:c.806T>G:p.Val269Gly and corresponding kinetic defect. A substitution of valine with phenylalanine in the same position has been previously described. This is the first reported case of a new CHRNA1 variant in a patient with SCCMS from South Asia. We also highlight the phenotype that would favour a genetic basis over an autoimmune one, in an adult presenting with fatigable weakness.
